ATE293688T1 - Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide - Google Patents

Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide

Info

Publication number: ATE293688T1
Authority: AT; Austria
Prior art keywords: arabinonucleotide; residues; antisense oligonucleotides; flanking; series
Prior art date: 2000-09-06

Application number

AT01969101T

Other languages

German (de)

English (en)

Inventor

Masad Jose Damha

Michael A Parniak

Chun-Nam Lok

Ekaterina Viazovkina

Original Assignee

Univ Mcgill

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-06

Filing date

2001-09-04

Publication date

2005-05-15

2001-09-04 Application filed by Univ Mcgill filed Critical Univ Mcgill

2005-05-15 Application granted granted Critical

2005-05-15 Publication of ATE293688T1 publication Critical patent/ATE293688T1/de

Links

ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 title abstract 4
108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
HMFHBZSHGGEWLO-HWQSCIPKSA-N L-arabinofuranose Chemical class OC[C@@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-HWQSCIPKSA-N 0.000 title 1
239000002214 arabinonucleotide Substances 0.000 abstract 6
108020004394 Complementary RNA Proteins 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 abstract 2
239000003184 complementary RNA Substances 0.000 abstract 2
108020000999 Viral RNA Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
238000003776 cleavage reaction Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
230000035897 transcription Effects 0.000 abstract 1
238000013518 transcription Methods 0.000 abstract 1
230000014616 translation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

AT01969101T 2000-09-06 2001-09-04 Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide ATE293688T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23041400P	2000-09-06	2000-09-06
PCT/CA2001/001252 WO2002020773A2 (fr)	2000-09-06	2001-09-04	Antisens chimerique d'analogues de l'arabinofuranose analogue et nucleotides de desoxyribose

Publications (1)

Publication Number	Publication Date
ATE293688T1 true ATE293688T1 (de)	2005-05-15

Family

ID=22865132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01969101T ATE293688T1 (de)	2000-09-06	2001-09-04	Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide

Country Status (8)

Country	Link
US (1)	US8178348B2 (fr)
EP (1)	EP1315807B1 (fr)
JP (1)	JP2004507272A (fr)
AT (1)	ATE293688T1 (fr)
AU (2)	AU2001289448B8 (fr)
CA (1)	CA2419563C (fr)
DE (1)	DE60110244T2 (fr)
WO (1)	WO2002020773A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69934227T2 (de) *	1998-06-19	2007-10-04	Mcgill University, Montreal	Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide
US8278103B2 (en) *	2002-02-01	2012-10-02	Mcgill University	Oligonucleotides comprising alternating segments and uses thereof
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2006045202A1 (fr)	2004-10-29	2006-05-04	Topigen Pharmaceuticals Inc.	Oligonucleotides antisens pour le traitement d'allergies et de proliferation de cellules neoplastiques
AU2007252192B2 (en)	2006-05-19	2013-10-17	Topigen Pharmaceuticals Inc.	Oligonucleotides affecting expression of phosphodiesterases
EP2285961A4 (fr)	2008-05-15	2012-10-17	Topigen Pharmaceuticals Inc	Oligonucléotides pour le traitement de l inflammation et de la prolifération des cellules néoplasiques
NZ601660A (en) *	2008-08-25	2014-05-30	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
GB201110239D0 (en) *	2011-06-17	2011-08-03	College The	Labelling method
AU2012308320C1 (en)	2011-09-14	2018-08-23	Translate Bio Ma, Inc.	Multimeric oligonucleotide compounds
US20150247141A1 (en)	2012-09-14	2015-09-03	Rana Therapeutics, Inc.	Multimeric oligonucleotide compounds
US20210340536A1 (en) *	2018-09-26	2021-11-04	AUM LifeTech, Inc.	2' fana modified foxp3 antisense oligonucleotides and methods of use thereof
US20220064636A1 (en) *	2018-10-05	2022-03-03	Ionis Pharmaceuticals, Inc.	Modified oligomeric compounds and uses thereof
CA3127243A1 (fr)	2019-01-22	2020-07-30	Korro Bio, Inc.	Oligonucleotides d'edition d'arn et leurs utilisations
US20200385713A1 (en)	2019-01-22	2020-12-10	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
EP3914260A4 (fr)	2019-01-22	2023-05-17	Korro Bio, Inc.	Oligonucléotides d'édition d'arn et leurs utilisations
CA3151789A1 (fr) *	2019-09-19	2021-03-25	Arnay Sciences, Llc	Composes et procedes utiles pour moduler l'epissage de genes
KR20240133795A (ko) *	2021-12-16	2024-09-04	발레리오 테라퓨틱스	신규한 컨쥬게이티드 핵산 분자 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5955589A (en) *	1991-12-24	1999-09-21	Isis Pharmaceuticals Inc.	Gapped 2' modified oligonucleotides
US5808040A (en) *	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5968748A (en) *	1998-03-26	1999-10-19	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human HER-2 expression
AU3465599A (en) *	1998-04-01	1999-10-18	Hybridon, Inc.	Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
DE69934227T2 (de)	1998-06-19	2007-10-04	Mcgill University, Montreal	Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide

2001
- 2001-09-04 EP EP01969101A patent/EP1315807B1/fr not_active Expired - Lifetime
- 2001-09-04 AU AU2001289448A patent/AU2001289448B8/en not_active Ceased
- 2001-09-04 JP JP2002525780A patent/JP2004507272A/ja active Pending
- 2001-09-04 AT AT01969101T patent/ATE293688T1/de not_active IP Right Cessation
- 2001-09-04 AU AU8944801A patent/AU8944801A/xx active Pending
- 2001-09-04 US US10/363,768 patent/US8178348B2/en not_active Expired - Fee Related
- 2001-09-04 WO PCT/CA2001/001252 patent/WO2002020773A2/fr not_active Ceased
- 2001-09-04 DE DE60110244T patent/DE60110244T2/de not_active Expired - Lifetime
- 2001-09-04 CA CA2419563A patent/CA2419563C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO2002020773A3 (fr)	2003-01-23
AU2001289448B2 (en)	2006-03-16
US20040038399A1 (en)	2004-02-26
WO2002020773A2 (fr)	2002-03-14
CA2419563C (fr)	2018-03-20
EP1315807B1 (fr)	2005-04-20
AU2001289448B8 (en)	2006-08-10
JP2004507272A (ja)	2004-03-11
DE60110244D1 (de)	2005-05-25
DE60110244T2 (de)	2006-01-19
US8178348B2 (en)	2012-05-15
CA2419563A1 (fr)	2002-03-14
EP1315807A2 (fr)	2003-06-04
AU8944801A (en)	2002-03-22

Legal Events

Date	Code	Title	Description
2005-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69934227D1 (de)	2007-01-11	Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
ATE293688T1 (de)	2005-05-15	Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide
Daubendiek et al.	1997	Generation of catalytic RNAs by rolling transcription of synthetic DNA nanocircles
WO2004015075A3 (fr)	2004-06-17	Arn interferant courts possedant une structure en epingle a cheveux contenant une boucle non nucleotidique
TNSN08252A1 (en)	2009-10-30	Sirna anti myosine va et depigmentation de la peau
ZA200304500B (en)	2003-11-18	Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
Matteucci et al.	1991	Deoxyoligonucleotides bearing neutral analogs of phosphodiester linkages recognize duplex DNA via triple-helix formation
Patel et al.	1996	Formation of chimeric DNA primer extension products by template switching onto an annealed downstream oligonucleotide.
JP2003219893A5 (fr)	2006-03-02
EP1513859A4 (fr)	2007-11-14	Suppresseur kinase de l'inactivation de ras pour traiter la tumorigenese induite par ras
WO2001083513A3 (fr)	2002-05-23	Modulation antisens de l'inhibiteur de l'expression de la fixation 1 a l'adn
EP3040423A3 (fr)	2016-10-26	Micro-arn et ses utilisations
KR20040028771A (ko)	2004-04-03	비시엘-2 디엔에이 효소
WO2000008140A3 (fr)	2000-05-18	Oligonucleotides antisens destines a inhiber l'expression de vegf
DE602004031946D1 (de)	2011-05-05	Das künstliche cpg single strand deoxidation-oligonukleotid und dessen antivirale anwendungen
EP1697498A4 (fr)	2007-10-31	Suppresseur de kinase d'inactivation de ras destine a la therapie de tumorigeneses induites par ras
WO2003031459A3 (fr)	2003-11-13	Modulation des genes dependants de l'expression stat-1
CA2331333A1 (fr)	1999-12-29	Constructions oligonucleotides antisense a base de .beta.-arabinofuranose et de ses analogues
IL159759A (en)	2012-05-31	History of oligoribonucleotide for deliberate inhibition of gene expression, medicinal preparations containing them, methods for their preparation and use
EP1073731B1 (fr)	2007-12-19	Enzyme d'acide nucleique de coupure d'un arn
JP2006514546A5 (fr)	2006-12-28
Hovig et al.	2001	Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA
WO2001051670A3 (fr)	2002-02-28	Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe
IT1320168B1 (it)	2003-11-18	Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide.
CA2330570C (fr)	2010-01-12	Enzyme d'acide nucleique de coupure d'un arn